Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Inclusion Criteria:

• Age 18-50 at initial treatment;

• Diagnosis of classical Hodgkin lymphoma (cHL), Diffuse Large B-cell lymphoma (DLBCL)or Primary mediastinal large B-cell lymphoma (PMBCL);

• Patients in Complete Remission (CR) after first-line therapy [ABVD (doxorubicin,bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicin ,cyclophosphamide, vincristine, procarbazine and prednisone) or ABVD-BEACOPP Pet-2guided treatment for cHL; R-CHOP (rituximab-cyclophosphamide, doxorubicin,vincristine and prednisone) for DLBCL; R-CHOP or R-DA-EPOCH (rituximab- Dose Adaptedetoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) for PMBCL);

• Patients in remission for a minimum 3 years since the last treatment and a maximumof 10 years;

• Cumulative doxorubicin/ adriamycin dose received of at least 200 mg/mq (4 cycles ofchemotherapy);

• Availability echocardiogram (ECG) and 2D-STE-echocardiography (Two-dimensionalspeckle strain echocardiography) performed no later than three months prior toenrollment;

• Signature of a written informed consent form indicating that the patient understandsthe purpose of and procedures required for the study and is willing to participatevoluntarily in the study.

Exclusion Criteria:

• Diagnosis of secondary cancer at baseline, except non-melanoma skin cancers andadequately treated cone-biopsied in situ carcinoma of the cervix;

• Second line chemotherapy of stem cell transplant;

• Not able to perform physical activity;

• Grade >/=3 neuropathy;

• Vertebral fractures or stenosis of the vertebral canal; other bone fracture;

• Cardiovascular disease: arrhythmia >/= grade 2, hypertension >/ grade 2, leftventricular dysfunction >/= grade 2 pericardial disease/effusion any grade,myocarditis any grade, pulmonary hypertension any grade, restrictive cardiomyopathyany grade valvular hearth disease >/= grade 2, right ventricular dysfunction >/=grade 2;

• Venous thromboembolism or arterial thrombosis during last 6 months;

• Hemorrhage/ bleeding >/= grade 2 during last 6 months;

• Chronic lymphedema (arms and/ or limbs);

• Rheumatic disease or inflammatory bowel disease in systemic treatment;

• Any pleural effusion;

• If female, the patient is pregnant;

• Unwilling to comply to all required visits and procedures for the duration of studyparticipation